-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with large adenomas are generally the first-line treatment of transsphenoidal surgery (TSS), among which dopamine agonists (DA) are the first choice
The variables to be measured are demographic and clinical characteristics: age, gender, amenorrhea, galactorrhea, mass effect (hypogonadism, hypopituitarism, vision defects, sinus invasion according to Knosp classification and sellar area involvement)
A commercial kit (Siemens Healthineers) was used to determine the serum PRL level by chemiluminescence immunoassay
Pituitary MRI images (baseline and follow-up) use 3T or 1.
The starting dose of CBG is 1-1.
Results: A total of 185 cases of prolactinoma, including 124 cases of microadenoma (67.
Figure 1 (A) Tumor shrinkage rate (%) and (B) Prolactin level (ng/mL) graph
Figure 1 (A) Tumor shrinkage rate (%) and (B) Prolactin level (ng/mL) graph
Figure 2 Individual differences in tumor size among the three groups of patients: Cabergoline responds well, cabergoline responds poorly, and patients who require transsphenoidal surgery
Figure 2 Individual differences in tumor size among the three groups of patients: Cabergoline responds well, cabergoline responds poorly, and patients who require transsphenoidal surgery
Figure 3 This figure shows the time to reach TS_50 (12 months after the start of CBG, the pituitary MRI assesses tumor shrinkage ≥ 50%)
Figure 3 This figure shows the time to reach TS_50 (12 months after the start of CBG, the pituitary MRI assesses tumor shrinkage ≥ 50%)
This study shows that tumor shrinkage within 3-4 months after CBG treatment is a good tool for predicting long-term efficacy and helps clinicians make more appropriate and personalized decisions
Biagetti B, Sarria-Estrada S, Ng-Wong YK,et al.
Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline.
Leave a message here
